Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2024-01-08 Major Shareholding Noti…
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is an official notice from the Autorité des marchés financiers (AMF) regarding a 'Déclaration de franchissement de seuils' (Declaration of crossing thresholds). It details that Citigroup Global Markets Limited has crossed the 5% ownership threshold in GENEURO SA. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2024-01-08 French
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Medical Officer (Anke Post) and the retirement of the previous one (David Leppert). This falls directly under the category of board or management changes.
2024-01-05 French
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new Chief Medical Officer (Anke Post) and the retirement of the previous one (David Leppert). This falls under the category of management changes, which is explicitly defined as 'Board/Management Information' (MANG).
2024-01-05 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the results of an interim analysis by an Independent Data Monitoring Committee regarding a clinical trial for temelimab. It provides updates on the trial's progress, safety, and efficacy findings, and mentions that results are expected in June 2024. This type of corporate announcement regarding clinical trial milestones and regulatory/committee updates is best classified as a Regulatory Filing (RNS) as it does not fit into specific categories like financial reports, proxy statements, or dividend notices.
2023-12-11 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the recommendation of an Independent Data Monitoring Committee (IDMC) regarding a clinical trial for temelimab. It provides an update on the status of a medical study rather than financial results, governance, or a formal report. As it is a corporate announcement regarding operational/clinical progress that does not fit into specific categories like earnings or M&A, it is classified as a general regulatory filing/announcement.
2023-12-11 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the completion of patient recruitment for a Phase 2 clinical trial. It provides details on the trial's methodology, the target protein (W-ENV), and the expected timeline for results. It does not fit into financial reporting categories like 10-K or IR, nor is it a simple report publication announcement. As it is a general regulatory/corporate announcement regarding company operations and clinical progress, it falls under the RNS (Regulatory Filings) category.
2023-11-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.